



Published in final edited form as:

*Nat Rev Rheumatol.* 2016 May ; 12(5): 269–281. doi:10.1038/nrrheum.2016.1.

## Metabolomics in rheumatic diseases: desperately seeking biomarkers

Monica Guma<sup>1</sup>, Stefano Tiziani<sup>2</sup>, and Gary S. Firestein<sup>1</sup>

<sup>1</sup>Division of Rheumatology, Allergy and Immunology, University of California San Diego School of Medicine, 9500 Gilman Drive, La Jolla, California 92093-0656, USA

<sup>2</sup>Department of Nutritional Sciences, University of Texas at Austin, 1400 Barbara Jordan Boulevard, Austin, Texas 78723, USA

### Abstract

Metabolomics enables the profiling of large numbers of small molecules in cells, tissues and biological fluids. These molecules, which include amino acids, carbohydrates, lipids, nucleotides and their metabolites, can be detected quantitatively. Metabolomic methods, often focused on the information-rich analytical techniques of NMR spectroscopy and mass spectrometry, have potential for early diagnosis, monitoring therapy and defining disease pathogenesis in many therapeutic areas, including rheumatic diseases. By performing global metabolite profiling, also known as untargeted metabolomics, new discoveries linking cellular pathways to biological mechanisms are being revealed and are shaping our understanding of cell biology, physiology and medicine. These pathways can potentially be targeted to diagnose and treat patients with immune-mediated diseases.

---

Endogenous and exogenous low-molecular-weight molecules (<1–1.5 kDa) in a biological sample are generally referred to as metabolites. For decades, the identification and quantification of metabolites was primarily determined by analytical chemists and biochemists using targeted analysis of specific subsets of compounds<sup>1–3</sup>. This metabolic profiling, or metabolite target analysis (BOX 1), revealed the chemical nature of important compounds including vitamins, cofactors and amino acids. With the advent of systems biology and the ‘omics’ revolution, metabolomics<sup>4,5</sup> has enabled the rapid, simultaneous measurement of thousands of metabolites from minimal amounts of sample. Metabolic datasets obtained using both metabolomics and stable-isotope-assisted metabolomics<sup>6–9</sup> have been used to feed into different mathematical modelling approaches, including metabolic flux analysis (see Supplementary information S1 (figure)).

---

Correspondence to M.G. mguma@ucsd.edu.

#### Author contributions

M.G. and S.T. researched data for the article. All authors contributed to discussion of content, writing the article and reviewing and editing the manuscript before submission.

#### Competing interests statement

The authors declare no competing interests.

#### SUPPLEMENTARY INFORMATION

See online article: S1 (figure) | S2 (table)

Genes are subject to epigenetic regulation, and proteins to post-translational modification, but metabolites are direct signatures of biochemical activity, and might be easier to correlate with phenotypes. The response of a biological system to disease status or therapeutic intervention can be reflected in specific patterns of metabolites. To ensure the inclusion of all relevant molecules, metabolomic approaches should ideally be untargeted, hypothesis-free, comprehensive analyses of metabolites followed by advanced data processing<sup>5</sup>. However, owing to the computational complexity of untargeted analyses, targeted studies are also conducted.

The metabolome is the complete set of metabolites within a biological sample. Metabolic pathways can interact and overlap (FIG. 1 and the Metabolic pathways — reference pathway). In samples from the human body, ~3,000–5,000 metabolites have been detected, and many have already been identified. The metabolomes of biofluid and tissue samples are affected not only by genetics, but also by lifestyle factors including diet, drugs, exercise, gut microbiota, health-to-disease status, hormonal homeostasis and age. Metabolites can be endogenous, including lipids, small peptides, amino acids, organic acids, vitamins, carbohydrates, thiols and nucleic acids (see Supplementary information S2 (table)) or exogenous, such as drugs, environmental contaminants, food additives, toxins and other xenobiotics. Lipids, amino acids and carbohydrates are the most abundant metabolites in plasma<sup>10</sup>.

## Abundant endogenous metabolites

### Lipids

Lipid metabolism, including uptake, transport, synthesis and degradation, is a complex process regulated by a number of signalling pathways. Lipids have important biological functions in energy storage, as structural components of cell membranes and as signalling molecules. The lipid components of biological membranes were originally considered to be merely structural, but considerable evidence now exists demonstrating the importance of lipid signalling via a variety of receptors<sup>11</sup> (TABLE 1). Alteration of lipid metabolism leads to changes in membrane composition and permeability, gene expression and protein distribution and function, as well as in cellular functions such as cell growth, proliferation, differentiation, survival, apoptosis, inflammation and motility, causing the development and progression of many diseases.

### Carbohydrates

Carbohydrates have crucial roles in metabolism and signalling (TABLE 1). The monosaccharide glucose is an important energy source, and increases in glucose uptake and glycolysis have been associated with increased cellular proliferation by generating ATP and providing substrates for the synthesis of proteins, nucleic acids and lipids. Carbon compounds produced during glycolysis can also be diverted into either the oxidative or the nonoxidative branches of the pentose-phosphate pathway (PPP) for nucleotide and cofactor biosynthesis and redox balance. Indeed, NADPH, the main reducing cofactor in the cytoplasm, is required to quench reactive oxygen species during cellular proliferation.

## Amino acids

Amino acids are nutrients and substrates for macromolecular synthesis. For example, glutamine, although not an essential amino acid, is well studied and highly abundant (~0.5 mM in blood). During cellular proliferation, glutamine provides nitrogen and carbon for the *de novo* synthesis of amino acids and synthesis of nucleotides through the hexosamine pathway, and can (particularly in hypoxic conditions associated with cancer) contribute to the generation of cytosolic acetyl coenzyme A, an intermediate in lipid biosynthesis<sup>12</sup> (Metabolic pathways — reference pathway).

## Bioactivity and metabolite crosstalk

Metabolites can participate in intercellular communication<sup>13</sup> (TABLE 1). Metabolite exchange between stromal and parenchymal cells is common and essential for the function of numerous tissues. In both cancer and inflammation, metabolism and cellular communication are altered. Lactate from tumour cells, for instance, promotes tumour angiogenesis via activation of the hypoxia-inducible transcription factor HIF-1 $\alpha$ <sup>14</sup>. Metabolic enzymes can also affect post-translational modification<sup>15</sup>.

Metabolites also have signalling roles in immune cells, such as the induction of IL-1 $\beta$  expression by succinate via activation of HIF-1 $\alpha$ <sup>16</sup>. Succinate and other metabolites such as acetyl coenzyme A are also involved in alteration of the epigenome<sup>17,18</sup>. Amino acids have been shown to affect cell signalling<sup>19</sup>, recruitment<sup>20</sup> and proliferation of immune cells,<sup>21</sup> and members of several different categories of lipids have been identified as signalling molecules and cellular messengers<sup>11</sup>.

Soluble inositol polyphosphates and membrane polyphosphoinositide lipids<sup>22</sup>, have numerous functions. Phosphatidylinositol (3,4,5)-trisphosphate, for example, modulates cell growth, proliferation and motility<sup>11</sup>. Ceramides and sphingosines have proapoptotic and antiproliferative actions<sup>23</sup>, but phosphorylation of sphingosine converts it to sphingosine-1-phosphate, which promotes cell growth and proliferation<sup>24</sup>. Eicosanoids<sup>25</sup> and lysophosphatidic acid<sup>11</sup> also have autocrine and paracrine actions through binding to a family of G-protein-coupled receptors.

## Metabolomics databases

Metabolomes vary considerably between tissues and biofluids, and databases have been developed for the large amounts of information generated in studies of different systems<sup>26</sup>. One of the most highly utilized is the [Human Metabolome Database](#) or HMDB<sup>27</sup>, an open-access resource containing detailed information on >40,000 metabolites. Other resources with information relating to compounds or spectroscopy are the [Kyoto Encyclopedia of Genes and Genomes \(KEGG\)](#)<sup>28</sup>, [LipidMaps](#)<sup>29</sup>, [PubChem](#)<sup>30</sup>, [Chemical Entities of Biological Interest \(ChEBI\)](#)<sup>31</sup>, [Madison Metabolomics Consortium Database \(MMCD\)](#)<sup>32</sup>, [METLIN](#)<sup>33</sup> and [MassBank](#)<sup>34</sup> databases. The [Metabolomics Standards Initiative \(MSI\)](#)<sup>35</sup> was created to help to avoid discrepancies between databases and to promote consistency and reproducibility between laboratories with different instrumentation and methods of analysis.

## State-of-the-art technologies

Profiling the metabolome is challenging, owing to the intrinsic heterogeneity of the compounds involved<sup>36–38</sup>, and it becomes even more problematic when absolute quantification of one or more biomarkers is required, particularly in the context of clinical studies<sup>39</sup>. Before performing any metabolite analyses, careful design of sample collection, data processing and data analysis is crucial to limit unwanted bias. Adding quality control during data acquisition is important to obtain reproducible results and ensure generation of meaningful data: if samples are not collected properly, or stored and processed uniformly, the data generated could be invalid. Sample collection, storage, and processing procedures are extremely important for the conduction of successful metabolomic studies, which also require careful design to minimize and account for the effects of factors such as gender, age, diet, fasting state, exercise and physical activity, the use of drugs, medications and other active substances, and the time of day of sample collection.

Metabolomic analysis can involve different analytical platforms. These methodologies include ultraviolet spectroscopy, Fourier transform infrared spectroscopy and Raman spectroscopy<sup>40</sup>, but the most commonly utilized platforms are NMR spectroscopy and mass spectrometry (MS), both of which have advantages and disadvantages (BOX 2).

### NMR spectroscopy

NMR spectroscopy, although having lower sensitivity than MS, is a robust metabolomic platform with several advantages. NMR is currently the best technique for chemical structure elucidation<sup>41</sup>; it requires only minimal sample preparation, and is nondestructive, inherently untargeted, highly reproducible<sup>42,43</sup> and intrinsically quantitative<sup>44–46</sup>. An advantage of NMR spectroscopy is the ability to bridge the gap between *in vitro*, *ex vivo* and *in vivo* studies, with the use of high-resolution magic-angle spinning to profile intact tissues and magnetic resonance spectroscopic imaging for *in vivo* applications<sup>47</sup>. Developments in the sensitivity and resolution of NMR instrumentation come about through improvements in the availability of superconducting materials, the strength of magnetic fields<sup>48</sup> and cryogenic probe technology<sup>49</sup>.

Historically, NMR probes required large sample sizes (500–600  $\mu\text{l}$ ), but advances in microprobe development now enable the analysis of samples  $\sim 30 \mu\text{l}$ <sup>50</sup>. Cooling microprobe coils with a stream of helium gas (20–30 K)<sup>51</sup> enables 60–80-fold increases in the NMR signal-to-noise ratio compared with conventional 5 mm room-temperature probes.

In the metabolomic profiling of biological samples, the majority of NMR spectra are acquired by 1D NMR for the high throughput required for screening purposes<sup>52</sup>. However, compared with 1D NMR, ultrafast and nonuniform sampling has shown potential to reduce signal overlap and acquisition time and to enhance signal sensitivity by increasing the dimensionality of NMR spectra<sup>53–55</sup>. In a study of the human urine metabolome<sup>56</sup>, high-resolution NMR detected and quantified >200 metabolites in an untargeted fashion, including >100 metabolites that were identified by NMR but not by other techniques. However, the need to increase the number of detected metabolites to obtain a more comprehensive

description of the metabolic status has motivated researchers to add — or to switch to — MS-based analysis<sup>56–61</sup>.

### Mass spectrometry

Currently available mass analysers<sup>62</sup> include triple quadrupole, quadrupole time-of-flight (TOF) and linear ion trap–Fourier transform ion cyclotron resonance, as well as orbitrap devices<sup>63,64</sup>. Metabolites can either be directly injected into the mass spectrometer as a mixture, or they can first be separated, by one of a variety of methods. Direct injection without separation into a high-mass-accuracy mass spectrometer (such as an orbitrap) is commonly called direct infusion MS<sup>65</sup> or shotgun MS<sup>66,67</sup>. This high-throughput, untargeted and comprehensive technique is ideal for a first metabolic screen, but the lack of initial separation means that metabolites with the same mass will overlap, interfering with identification.

Gas-chromatography–MS (GC–MS) and liquid-chromatography–MS (LC–MS) are the most common MS-based metabolomics methodologies. GC–MS is ideal for the analysis of volatile compounds, and is also commonly used for targeted metabolic analysis of organic acids, amino acids, sugars and fatty acids, following chemical derivatization. GC–MS is one of the most robust MS-based techniques for metabolomic<sup>68</sup> and lipidomic quantification<sup>69</sup>, but GC–MS systems commonly have low-resolution spectrometers, and high-resolution LC–MS platforms are increasingly being utilized for both untargeted and targeted metabolic analyses. In LC–MS, in addition to choosing between MS systems, the choice of liquid chromatography column (regardless of the use of high pressure or ultrahigh pressure) is vital to the success of the profiling experiment, and in general multiple columns are necessary for optimal detection of metabolites<sup>70</sup>. LC–MS systems can detect thousands of features and identify hundreds of compounds<sup>71</sup>. However, many features cannot be identified using available databases. Tandem MS (MS/MS)<sup>27,29,33</sup> can aid in identification; alternatively, spiking a sample with a chemical standard can help to identify a putative metabolite<sup>72</sup>.

### Stable-isotope-assisted metabolomics

Identification and quantification of metabolic biomarkers can provide a metabolic snapshot of the status of a living organism, but cannot provide an unambiguous picture of the metabolic flux between cellular compartments. For instance, an increase in the concentration of a metabolite can be associated with either the upregulation of the enzyme that synthesizes the metabolite or the downregulation of the one that consumes it. Stable-isotope labelling (with an isotope such as <sup>13</sup>C) of a precursor (such as glucose or glutamine) enables tracking of its cellular fate *in vitro* or *in vivo*<sup>53,73</sup>. Datasets from such experiments can be fed into mathematical models such as metabolic flux analysis<sup>6–9,74,75</sup> (see Supplementary information S1 (figure)).

### Metabolomic studies in rheumatic disease

Metabolomics can provide important information relating to pathogenesis and disease activity in rheumatic conditions. The fundamental rationale in metabolomics is that perturbations in a biological system caused by disease will lead to correlated changes in the

concentrations of certain metabolites. Although in some situations (such as genetic metabolic disease) the identification of a single, robust diagnostic metabolite might be possible, in many others (including rheumatic disorders) the perturbations involve the activation of multiple pathways. NMR and MS can identify biomarkers and patterns of change that are highly discriminatory for these perturbations and for disease states. Disease-specific metabolic pathways can indicate potential therapeutic targets, to enable alteration of the metabolic activity implicated in pathogenesis. They can also identify disease-specific biomarkers.

Biomarkers are anatomical, physiological, biochemical or molecular variables or imaging features that enable diagnosis and prognosis of disease and evaluation of the effects of treatment. The accessibility of biomarkers is important, and blood and urine are more accessible than synovial tissues or fluids in joints affected by rheumatic diseases. Despite the relative inaccessibility, metabolic profiling using intact tissue has gained momentum as an approach for understanding the molecular basis of disease.

The study of metabolomics in inflammatory disease represents a new approach to identifying biomarkers beyond autoantibody profiling and transcriptomics. Several metabolomics studies have focused on the identification of metabolites associated with rheumatic diseases or the prediction of response to treatment. In general, the results of these studies have been promising, but most included small numbers of patients, with heterogeneous clinical characteristics and treatments, and require confirmation<sup>76</sup>. Studies to identify correlations between metabolomic profiles and inflammation, bone and cartilage damage and the effects of therapeutic intervention are needed. The inclusion of normal controls matched for age and sex, and of populations affected by other arthritic diseases, as well as validation cohorts will help to determine whether metabolic signatures can distinguish between subsets of patients and help in diagnosis and prognosis.

The metabolomics of rheumatic disease have been studied in humans and in murine models. Some elements of metabolism are similar in different species, and biomarker discovery might benefit from the use of targeted animal models in which induction of disease and treatment can be controlled, and correlations between the metabolomes of serum and joints can be evaluated.

### **Systemic lupus erythematosus (SLE)**

Alteration of the metabolic profile in SLE has been studied by <sup>1</sup>H-NMR on serum samples obtained from patients with SLE ( $n = 64$ ), patients with rheumatoid arthritis (RA;  $n = 30$ ) and healthy controls ( $n = 35$ )<sup>77</sup>. In patients with SLE, significant reductions in the levels of valine, tyrosine, phenylalanine, lysine, isoleucine, histidine, glutamine, alanine, citrate, creatinine, creatine, pyruvate, cholesterol, glycerol and formate were detected in comparison with the control population. Apart from the decrease in creatine, the same profile was detected in patients with RA as in those with SLE, suggesting a correlation of these metabolic changes with inflammation.

A comparison of sera from 20 patients with SLE and nine healthy controls using LC-MS and GC-MS platforms identified >100 metabolites that were significantly different in the

SLE population<sup>78</sup>. Validation of these findings was performed with an independent cohort of 38 patients with SLE, along with 20 patients with RA and 14 healthy controls<sup>78</sup>. Compared with the controls, sera from patients with SLE showed evidence of profoundly dampened glycolysis, Krebs cycle, fatty acid  $\beta$ -oxidation and amino acid metabolism, suggesting reduced energy biogenesis from all sources<sup>78</sup>. Whereas levels of long-chain fatty acids were significantly reduced, those of medium-chain fatty acids were elevated in association with SLE. The metabolomes in patients with SLE exhibited profound lipid peroxidation reflective of oxidative damage, with deficiencies in the cellular antioxidant glutathione, as well as methyl group donors required for glutathione regeneration<sup>78</sup>.

Urinary metabolites that discriminate between proliferative and pure membranous lupus nephritis have been identified with NMR spectroscopy in a pilot study involving seven patients<sup>79</sup>. Urinary citrate levels were eightfold lower in patients with class V lupus nephritis than in those with class III or class IV disease ( $P < 0.05$ ), in whom the levels were normal. Conversely, levels of urinary taurine were mostly normal in patients with class V disease, but  $>10$ -fold lower in those with class III or class IV disease, suggesting that these urinary metabolites can serve as biomarkers to help discriminate between different classes of lupus nephritis.

Preclinical models can provide important clues to help refine searches for biomarkers in human disease. Rapid-resolution liquid chromatography coupled with quadrupole TOF-MS (RRLC-Q-TOF-MS) has been utilized to acquire metabolic profiles of serum samples obtained from mice treated with single intraperitoneal injections of pristane, which induces an SLE-like disease characterized by the production of autoantibodies<sup>80</sup>. These mice had altered levels of 13 metabolites associated with the metabolism of unsaturated fatty acids (UFAs), phospholipids and tryptamine<sup>80</sup>.

The results of these metabolomics studies suggest that an imbalance in lipid profiles might contribute to disease, especially in relation to arachidonic acid metabolism. Evidence derived from studies involving both human and murine<sup>80</sup> samples implicates disorder of UFA metabolism in SLE and SLE-like disease. UFAs have an important role in the maintenance of normal physiological functions, including regulation of the immune response. Among the UFA metabolites that are differentially regulated in SLE, 12-hydroxyicosatetraenoic acid (12[S]-HETE) is an active metabolite of arachidonic acid that is produced through the arachidonate 12-lipoxygenase pathway. This metabolite has a prominent role in the promotion of inflammation, causes the accumulation of extracellular matrix and induction of mesangial-cell hypertrophy, and is involved in the pathogenesis of diabetic nephropathy<sup>81</sup>. An increase in the level of 12(S)-HETE in SLE might promote kidney inflammation and cell hypertrophy, thereby aggravating the symptoms of kidney disease. Other metabolites, such as 5-hydroxyicosatetraenoic acid and leukotriene B<sub>4</sub>, are also elevated in SLE and can contribute to the pro-inflammatory milieu and prothrombotic state.

### **Osteoarthritis (OA)**

The alteration of the metabolic profile in OA has been studied in media from the culture of synovial explants dissected from diseased joints in patients with no OA or early OA

compared with end-stage OA (11 patients per group)<sup>82</sup>. The samples were subjected to global metabolic profiling with LC–MS and GC–MS, resulting in the identification of 11 compounds with significantly different concentrations in the two groups<sup>82</sup>. The metabolite profiles suggested that abnormal degradation of collagen contributes to an ‘OA signature’ in the blood. However, given the discrepancy in the mean ages of the patients (67 years in the end-stage OA group versus 18 years in the group with no OA or early OA), some of the observed metabolite changes could be secondary to age-related chondrocyte changes, rather than being specific to OA<sup>82</sup>.

A study in which OA phenotypes were classified by the results of metabolomic analyses was limited by the absence of synovial fluid samples from healthy people, and by the failure to associate the phenotypes with clinical data<sup>83</sup>. In another study, synovial fluid samples were collected from 55 patients with symptomatic chronic knee OA and 12 normal human cadaveric knee joints; this study also included a validation group and was age-matched<sup>84</sup>. The samples were analysed by <sup>1</sup>H-NMR and GC–MS, and the differences in metabolic profiles were indicative of hypoxic conditions in diseased and inflamed knee joints, and high energy requirements in patients with OA<sup>84</sup>. Similar alterations have been described previously<sup>84–88</sup>, with some variations in the involvement of specific metabolites, possibly owing to the use of animal models<sup>84–86,88</sup> or the lack of a healthy human control group<sup>87</sup>. These studies did not include samples from other inflammatory arthritides, so further studies are needed to determine the specific metabolomic profile of OA.

Studies have also been conducted with serum or urine samples to determine the metabolomic signature of OA. In a study with MS/MS analysis of serum samples from patients with knee OA, the ratio of branched-chain amino acids (valine and leucine) to histidine was described as a novel biomarker<sup>89</sup>. Analysis by <sup>1</sup>H-NMR of urine samples from 47 controls and 45 individuals with OA identified a metabolite profile suggestive of altered energy metabolism that was strongly associated with OA<sup>90</sup>. A comparison of plasma and synovial fluid from patients with primary knee OA (with metabolic profiling by MS/MS)<sup>91</sup> found modest correlation between metabolite concentrations, but higher correlation between metabolite ratios, which are considered proxies for enzymatic reaction rates. Assessment of metabolite ratios should be considered when using plasma as a surrogate for synovial fluid in biomarker identification in OA and probably in other diseases.

### RA and inflammatory arthritides

Metabolic profiling has been explored in synovial fluid in inflammatory arthritides. Synovial fluid samples from 38 patients with RA, ankylosing spondylitis, Behçet disease or gout were analysed by GC–MS<sup>92</sup>, and 20 metabolites were selected as potential biomarkers to discriminate RA from the other conditions. Higher abundance of a number of metabolites in samples from patients with RA indicated activation of energy pathways such as the tricarboxylic acid (TCA) cycle, as well as amino-acid metabolism<sup>92</sup>. However, the levels of inflammatory markers were not measured, so these changes could be related to a greater degree of inflammation in RA than in the other conditions.

Untargeted screening of lipids in synovial fluid samples from patients with RA has been performed with an LC–MS/MS screening platform<sup>93</sup>. Approximately 70 different



components from distinct lipid classes were detected, although no control group was analysed<sup>93</sup>. A targeted lipidomics strategy was developed for quantification of anti-inflammatory bioactive fatty acids maresin 1, lipoxin A4 and resolvin D5. In a study of synovial fluid samples from unaffected controls ( $n = 9$ ) and from patients with early OA ( $n = 17$ ), late OA ( $n = 13$ ) or RA ( $n = 30$ ), phospholipid species were quantified by MS/MS<sup>94</sup>. Several lipid classes were identified, and the highest concentrations (with the exception of phosphatidylserine) were observed in late OA<sup>94</sup>. Samples from patients with RA also had higher concentrations of these lipids than control samples. These observations suggest that phospholipid changes are secondary to cartilage damage; their production could protect cartilage from friction-induced mechanical damage. However, significant differences in age and gender between groups made it difficult to conclude that these differences were disease-specific<sup>94</sup>.

Studies have also been carried out to identify metabolites in serum and plasma that can help in diagnosis, prognosis and the prediction and measurement of response to treatment in rheumatic diseases. In a comparison of serum metabolic signatures in OA, RA, ankylosing spondylitis and gout by MS<sup>95</sup>, homoserine, 4,8-dimethylnonanoyl carnitine, glyceraldehyde, lactic acid, dihydroxyfumaric acid and aspartic acid were identified as candidate markers in the four types of arthritis, compared with healthy controls. In another study, with <sup>1</sup>H-NMR characterization of serum samples from patients with established RA, early arthritis and healthy controls, levels of several metabolites, such as 3-hydroxybutyrate, glucose, lactate, and urea, were correlated with the extent of inflammation<sup>96</sup>.

The data from these studies suggest that upregulation of glycolysis, the TCA cycle, metabolism of glycine and serine, fatty acid and amino acid metabolism occurs in all these inflammatory conditions, indicating that these pathways might not be suitable sources of disease-specific biomarkers. Further studies are required to complement these investigations and others involving RA and inflammatory arthritides (such as psoriatic arthritis and ankylosing spondylitis) to identify specific biomarkers for each condition<sup>97–101</sup>.

In a preclinical study<sup>102</sup>, a serum metabolomic method involving RRLC–Q-TOF-MS was performed for an evaluation of the metabolic changes in collagen-induced arthritis (CIA) in rats. Herein, 10 metabolites (suggestive of dysregulation of the arachidonic acid and phospholipid metabolic networks) were found to be associated with the pathogenesis of CIA. The relationships between eicosanoid metabolism, arthritis and inflammation have been reviewed previously<sup>25</sup>.

Attempts to correlate metabolite profiles and response-to-treatment have had promising results. In one study<sup>103</sup>, a <sup>1</sup>H-NMR metabolomic approach was applied to 38 patients with active RA. After 24 weeks, patients who responded to methotrexate treatment showed significant elevations in serum levels of uric acid, taurine, methionine, glycine, histidine and hypoxanthine, and reductions in levels of uracil, TMAO,  $\alpha$ -oxoglutarate, aspartate, and tryptophan, compared with patients in whom methotrexate was not effective<sup>103</sup>. NMR analysis of urine from 16 patients with RA and 20 with psoriasis (before anti-TNF therapy)<sup>104</sup> identified upregulation of histamine, glutamine, phenylacetic acid, xanthine, xanthurenic acid and creatinine, and downregulation of ethanolamine, p-

hydroxyphenylpyruvic acid and phosphocreatine in samples from patients who had a good response to therapy.

## Disease-specific metabolic pathways

Because metabolic pathways are so closely related, the alteration of one of these pathways will probably have wider effects on the metabolome. Analysis of metabolomics data might identify specific metabolic pathways and activated signalling pathways associated with the pathogenesis of a disease. Metabolic changes described in specific cell types or bioactive metabolites involved in the pathogenesis of the disease<sup>105</sup> might also correlate with changes observed in metabolomics studies.

Many signalling pathways activated under inflammatory conditions have profound effects on cellular metabolism, supporting cell growth and survival. These adaptations must be implemented in the stressful and dynamic microenvironment of inflamed tissues, where concentrations of crucial nutrients such as glucose, glutamine and oxygen are spatially and temporally heterogeneous. Therefore, multiple molecular mechanisms converge to alter core cellular metabolism and provide support for three basic needs of dividing cells: ATP generation to maintain energy status; biosynthesis of macromolecules; and tight maintenance of appropriate cellular redox status. Cells acquire alterations to the metabolism of the major classes of macromolecules — carbohydrates, proteins, lipids and nucleic acids. The study of cancer cell metabolism has successfully identified cancer-specific metabolic changes, but other cell types, such as lymphocytes and stromal cells, are also subject to major metabolic challenges upon activation, and adopt specific metabolic programmes to adapt to changing environmental conditions.

Immune cells have specific metabolic signatures related to effector function. Metabolic changes occurring in T cells<sup>106–110</sup>, macrophages<sup>111</sup> and dendritic cells<sup>112,113</sup> have been extensively reviewed, but less information is available with regard to stromal cells, including fibroblasts, and endothelial cells<sup>105</sup>. Emerging evidence also indicates that metabolism is not only involved in the determination of cell differentiation and function, but also that metabolic changes contribute to the pathogenesis of cancer, diabetes and inflammatory diseases<sup>105</sup>. Some of these changes are summarized in FIG. 2 and BOX 3.

## SLE

Glycolysis and mitochondrial oxidative metabolism are elevated in CD4<sup>+</sup> T cells from lupus-prone mice (compared with nonautoimmune controls) and also in CD4<sup>+</sup> T cells from patients with SLE; the elevation correlates with the patients' activation status, and IFN- $\gamma$  production is significantly reduced by metformin<sup>114</sup>. Treatment with a combination of metformin and 2-deoxy-D-glucose normalizes T-cell metabolism and reverses changes in the levels of disease biomarkers in animal models of lupus, suggesting a promising therapeutic approach for SLE<sup>114</sup>. However, serum metabolomics in patients with SLE have shown reduced glycolysis and Krebs cycle activity relative to healthy controls, and the contribution of these pathways to SLE pathogenesis is yet to be determined<sup>78</sup>.

CD4<sup>+</sup> T cells from patients with SLE display an altered profile of lipid-raft-associated glycosphingolipids compared with those from healthy controls<sup>115</sup>. Glycosphingolipids are essential for many cellular processes and are enriched predominantly in lipid rafts, influencing a range of T-cell functions including T cell receptor-mediated signalling and apoptosis, as well as recycling and endocytosis of membrane-associated receptors and signalling molecules. Inhibition of glycosphingolipid biosynthesis *in vitro* normalizes glycosphingolipid metabolism, corrects CD4<sup>+</sup> T-cell signalling and functional defects, and decreases anti-double stranded DNA (dsDNA) antibody production by autologous B cells in patients with SLE<sup>115</sup>. In metabolomics studies, no changes in this subset of lipids have been detected in blood, although further *in vivo* and *in vitro* studies are needed to determine if these particular T-cell metabolic changes can be detected.

## RA

The observation of increases in serum lactate in metabolomics studies conducted in the setting of inflammatory arthritides, including RA, suggests an alteration of glycolysis. However, the metabolic status of naive CD4<sup>+</sup> T cells has been examined in patients with RA, thereby excluding T cells that are directly involved in the inflammatory process itself. These naive RA T cells did not produce as much ATP and lactate as naive T cells from healthy, age-matched controls, although they proliferated vigorously<sup>116</sup>. Molecular analysis of the underlying defect responsible for this metabolic alteration identified 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) as a rate-limiting enzyme in the glycolytic pathway that was significantly decreased in T cells from patients with RA, compared with healthy controls. Fibroblast-like synoviocytes (FLSs) from patients with RA also have a higher baseline glycolytic rate than FLSs from patients with OA<sup>117,118</sup>. Expression of GLUT-1 (solute carrier family 2, facilitated glucose transporter member 1) also correlated with migration and expression of metalloproteinases. Notably, glucose deprivation or treatment with glycolytic inhibitors such as 2-deoxy-D-glucose and bromopyruvate impaired cytokine secretion, proliferation and migration in FLSs, and glycolytic inhibition by bromopyruvate administered *in vivo* in a serum-transfer animal model significantly decreased arthritis severity compared with untreated animals<sup>118</sup>. Thus, the increase in lactate detected in metabolomics studies<sup>95,96</sup> could be secondary to the increase in glycolysis in FLSs.

The choline pathway is highly active in FLSs<sup>119</sup>. Choline kinase- $\alpha$  (CK), the enzyme that catalyses the first step in the cytidine-diphosphate–choline pathway, is essential for phosphatidylcholine production. In comparison with healthy tissue, elevated levels of CK have been associated with malignant transformation, invasion and metastasis in some human cancers<sup>120–124</sup>. CK is expressed in synovial tissue in RA and in cultured FLSs; furthermore, a CK inhibitor suppresses the aggressive properties of cultured RA FLSs, including cell migration and resistance to apoptosis<sup>119</sup>. In a serum-transfer model of arthritis, pharmacological CK inhibition (compared with vehicle-only) prevented development of arthritis when administered before serum transfer, and significantly decreased levels of markers of arthritis in treatment of established disease<sup>119</sup>. Notably, in metabolomics studies, choline levels have been correlated with the degree of inflammation in RA, and several lipid alterations have been identified in RA samples<sup>93,104</sup>.

Sphingosine kinase 1 (SPK-1) phosphorylates sphingosine to make sphingosine-1-phosphate (S1P), a bioactive lipid involved in the pathogenesis of several autoimmune diseases<sup>24</sup>. SPK-1 blockade suppresses the release of cytokines and MMP-9 in peripheral blood mononuclear cells from patients with RA. In addition, downregulation of SPK-1 — either by an siRNA approach or in transgenic mice expressing human TNF and deficient in SPK-1 — limits synovial inflammation and joint pathology<sup>125,126</sup>. The synovia and synovial fluids of patients with RA exhibit significantly higher levels of S1P than those of patients with OA<sup>127</sup>.

Activated FLSs from arthritic human patients and animal models express autotaxin, which catalyses the conversion of lysophosphatidylcholine to lysophosphatidic acid<sup>128–130</sup>. This expression is induced by TNF, which also acts synergistically with lysophosphatidic acid to induce fibroblast activation and effector functions<sup>130</sup>. Conditional genetic ablation of autotaxin expression in mesenchymal cells, including FLSs, results in disease attenuation in animal models of arthritis. Notably, high levels of lysophosphatidylcholine and low ratios of phosphatidylcholine to lysophosphatidylcholine in plasma represent a reliable measure of inflammation<sup>131</sup>.

## Metabolic targeting in rheumatic diseases

The metabolic rewiring of cancer cells and immune cells has been viewed as a promising source of drug targets<sup>132–138</sup>. Resetting the altered metabolomes in these diseases, either by targeting selected molecules or by supplementing the diet with essential metabolites, such as fatty acids, offers novel opportunities for disease modulation. Several different approaches have been explored, leading to the identification of agents that are now close to entering clinical evaluation. Few metabolic inhibitors have been developed so far, reflecting the recent rediscovery of the field, as well as concerns regarding reproducibility of results and toxicity in cells undergoing intensive proliferation. Whether this approach will result in effective drugs for the treatment of rheumatic diseases, with effects beyond those of biological and kinase-inhibitor therapies, remains to be determined.

Rheumatologists already use the metabolic inhibitors methotrexate and leflunomide for the treatment of inflammatory arthritis<sup>139</sup>. Teriflunomide, the active metabolite of leflunomide, inhibits the mitochondrial enzyme dihydroorotate dehydrogenase. This enzyme is involved in *de novo* synthesis of pyrimidines, including uridine monophosphate (UMP), which is required for the synthesis of DNA and RNA; thus, leflunomide inhibits the reproduction of rapidly dividing cells, especially lymphocytes. Methotrexate, developed as a folic acid analogue, inhibits purine and pyrimidine synthesis, which accounts for its efficacy in the treatment of cancer, as well as for some of its toxicity. Other consequences of methotrexate treatment, such as adenosine accumulation, might also contribute to its disease-modifying effect in RA.

Some drugs that target altered metabolism in cancer could also have therapeutic value in rheumatic disease. Attempts to block aerobic glycolysis in tumour cells have not yet been effective<sup>140,141</sup>. Therapeutic approaches targeting numerous points in the glycolytic process are currently being evaluated, including inhibition of lactate dehydrogenase<sup>142</sup> and

inactivation of the glucose-uptake enzyme GLUT-1 (REF. 143) and monocarboxylate transporters<sup>144</sup>, which are responsible for conveying lactate across the plasma membrane. Interest is also being refocused on interventions that preferentially target the inducible hexokinase-2 isoform rather than the ubiquitous and constitutively expressed hexokinase-1 (REFS 145–147). Hexokinases control the first committed step of glucose metabolism. Expression of hexokinase-2 is restricted in normal adult tissues, making it an attractive target for selective inhibition, which could be safer than global regulation of glycolysis.

Ligand binding to G-protein-coupled receptors induces dissociation of heterotrimeric G proteins, releasing  $\beta\gamma$  subunits that activate phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit- $\gamma$  isoform (PI3K $\gamma$ ) to produce large, transient elevations in levels of phosphatidylinositol (3,4,5)-trisphosphate (PIP<sub>3</sub>)<sup>22,148</sup>. The lipid kinase PI3K $\gamma$  integrates multiple signals from chemokines, complement fragments, formylated bacterial peptides and other stimuli, and is essential for chemokine-induced leukocyte migration *in vivo*. PI3K $\gamma$  is the target of considerable pharmacological efforts to treat inflammatory disease<sup>149</sup>. Inhibitors of PI3K $\gamma$  have shown therapeutic effects in mouse models of RA and SLE, attenuating the migration of neutrophils and lymphocytes, respectively, into inflamed tissue<sup>149</sup>.

The sphingosine kinase pathway is another target<sup>24</sup>. Fingolimod, when phosphorylated by SPK-1, functions as an S1P-receptor agonist and targets four of the five known S1P receptors<sup>24</sup>. Fingolimod interferes with the exit of lymphocytes from lymph nodes — attenuating autoimmune disease such as multiple sclerosis — and is under consideration for treatment of other inflammatory and allergic conditions<sup>150</sup>.

As high proliferation rates entail a considerable demand for the generation of novel phospholipid bilayers, targeting *de novo* lipogenesis<sup>151</sup> or glutaminolysis<sup>152</sup> also constitutes a rational approach for metabolic targeting. Several enzymes involved in these molecular circuitries, including fatty acid synthase<sup>153</sup>, ATP citrate lyase<sup>154</sup>, acetyl-coenzyme A carboxylases<sup>155</sup>, choline kinase<sup>156,157</sup>, monoglyceride lipase<sup>158</sup> and 3-hydroxy-3-methylglutaryl coenzyme A reductase<sup>159</sup>, have been ascribed critical roles in oncogenesis or tumour progression *in vivo*, and might be reasonable therapeutic targets in rheumatic disease.

In addition to assessing whether therapies ultimately cause changes in metabolic pathways, metabolomics analysis can also measure drug pharmacokinetics<sup>160</sup>. Pharmacometabolomics has the capability to monitor how patients respond metabolically to drugs, and to determine whether the metabolic response is correlated with inflammation, adverse events and response.

## Future directions

The science of metabolomics in the context of disease is young, but has seen rapid and impressive progress. New technologies are now being developed to complement existing methods; for example, metabolomic genome-wide association studies (mGWAS) integrate multiple layers of molecular data<sup>161–164</sup>. Metabolomic data can be quantitative, and

mGWAS can uncover genetic variants that affect metabolite levels. Associations between single-nucleotide polymorphisms and specific metabolites indicate the biological mechanisms that underlie the genetic changes.

The influence of the microbiome on the metabolome is an area of increasing interest<sup>165–167</sup>. Perturbations of intestinal microbiota composition or function could have important roles in the development of diseases associated with altered metabolism, because intestinal microbiota can regulate the absorption, metabolism and storage of host metabolites. Dysbiosis of intestinal microbiota can directly perturb host immune regulatory networks. For example, butyrate, acetate and propionate — the main bacterially derived short-chain fatty acids (metabolites from bacterial fermentation of dietary fibre, highly enriched in the colon) — control differentiation and function of mucosal T<sub>REG</sub> cells<sup>168</sup>. These relationships suggest that intestinal microbial function should be incorporated into an in-depth study of the prominent disorders of metabolism and the immune system in rheumatic diseases, and the possibility of treatment by regulation of the intestinal microbiota.

## Conclusions

Metabolomics encompasses a powerful suite of technologies that enable the analysis of a wide range of small molecules that are involved in many aspects of physiology and pathology. Characterization of the differences in the metabolome between healthy and diseased states can improve our understanding of the mechanisms underlying pathological processes. As technology advances and our understanding of metabolic perturbations in rheumatic disease grows, new therapeutic targets and diagnostic tests will undoubtedly emerge. This process will require collaborations between clinicians, laboratory scientists and bioinformaticians. Ultimately, scientific advances must be translated into easily accessible, structured data that can be used by clinicians at the point-of-care for decision-making in the management of patients.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## References

1. Dalglish CE, Horning EC, Horning MG, Knox KL, Yarger K. A gas-liquid-chromatographic procedure for separating a wide range of metabolites occurring in urine or tissue extracts. *Biochem J.* 1966; 101:792–810. [PubMed: 16742460]
2. Efron ML, Young D, Moser HW, MacCready RA. A simple chromatographic screening test for the detection of disorders of amino acid metabolism: a technic using whole blood or urine collected on filter paper. *N Engl J Med.* 1964; 270:1378–1383. [PubMed: 14152868]
3. Henneman DH, Henneman PH. Effects of human growth hormone on levels of blood urinary carbohydrate and fat metabolites in man. *J Clin Invest.* 1960; 39:1239–1245. [PubMed: 14401058]
4. Fiehn O. Metabolomics — the link between genotypes and phenotypes. *Plant Mol Biol.* 2002; 48:155–171. [PubMed: 11860207]
5. Patti GJ, Yanes O, Siuzdak G. Innovation: metabolomics: the apogee of the omics trilogy. *Nat Rev Mol Cell Biol.* 2012; 13:263–269. [PubMed: 22436749]
6. Lane AN, Fan TWM, Higashi RM. Stable isotope-assisted metabolomics in cancer research. *IUBMB Life.* 2008; 60:124–129. [PubMed: 18380001]

7. Mueller D, Heinzle E. Stable isotope-assisted metabolomics to detect metabolic flux changes in mammalian cell cultures. *Curr Opin Biotechnol.* 2013; 24:54–59. [PubMed: 23142545]
8. Creek DJ, et al. Stable isotope-assisted metabolomics for network-wide metabolic pathway elucidation. *Anal Chem.* 2012; 84:8442–8447. [PubMed: 22946681]
9. Hiller K, Metallo C, Stephanopoulos G. Elucidation of cellular metabolism via metabolomics and stable-isotope assisted metabolomics. *Curr Pharm Biotechnol.* 2011; 12:1075–1086. [PubMed: 21466455]
10. Quehenberger O, Dennis EA. The human plasma lipidome. *N Engl J Med.* 2011; 365:1812–1823. [PubMed: 22070478]
11. Wymann MP, Schneider R. Lipid signalling in disease. *Nat Rev Mol Cell Biol.* 2008; 9:162–176. [PubMed: 18216772]
12. Anastasiou D, Cantley LC. Breathless cancer cells get fat on glutamine. *Cell Res.* 2012; 22:443–446. [PubMed: 22212478]
13. Wang T, Liu G, Wang R. The intercellular metabolic interplay between tumor and immune cells. *Front Immunol.* 2014; 5:358. [PubMed: 25120544]
14. Ruan GX, Kazlauskas A. Lactate engages receptor tyrosine kinases Axl, Tie2, and vascular endothelial growth factor receptor 2 to activate phosphoinositide 3-kinase/Akt and promote angiogenesis. *J Biol Chem.* 2013; 288:21161–21172. [PubMed: 23754286]
15. Wei X, et al. De novo lipogenesis maintains vascular homeostasis through endothelial nitric-oxide synthase (eNOS) palmitoylation. *J Biol Chem.* 2011; 286:2933–2945. [PubMed: 21098489]
16. Tannahill GM, et al. Succinate is an inflammatory signal that induces IL-1 $\beta$  through HIF-1 $\alpha$ . *Nature.* 2013; 496:238–242. [PubMed: 23535595]
17. Mills E, O'Neill LA. Succinate: a metabolic signal in inflammation. *Trends Cell Biol.* 2014; 24:313–320. [PubMed: 24361092]
18. Kaelin WG Jr, McKnight SL. Influence of metabolism on epigenetics and disease. *Cell.* 2013; 153:56–69. [PubMed: 23540690]
19. Xiao F, et al. Effects of individual branched-chain amino acids deprivation on insulin sensitivity and glucose metabolism in mice. *Metabolism.* 2014; 63:841–850. [PubMed: 24684822]
20. Becker JC, Andersen MH, Schrama D, Thor Straten P. Immune-suppressive properties of the tumor microenvironment. *Cancer Immunol Immunother.* 2013; 62:1137–1148. [PubMed: 23666510]
21. Yan Z, Garg SK, Kipnis J, Banerjee R. Extracellular redox modulation by regulatory T cells. *Nat Chem Biol.* 2009; 5:721–723. [PubMed: 19718041]
22. Bunney TD, Katan M. Phosphoinositide signalling in cancer: beyond PI3K and PTEN. *Nat Rev Cancer.* 2010; 10:342–352. [PubMed: 20414202]
23. Huang C, Freter C. Lipid metabolism, apoptosis and cancer therapy. *Int J Mol Sci.* 2015; 16:924–949. [PubMed: 25561239]
24. Gonzalez-Cabrera PJ, Brown S, Studer SM, Rosen H. S1P signaling: new therapies and opportunities. *FI000Prime Rep.* 2014; 6:109. [PubMed: 25580263]
25. Korotkova M, Jakobsson PJ. Persisting eicosanoid pathways in rheumatic diseases. *Nat Rev Rheumatol.* 2014; 10:229–241. [PubMed: 24514915]
26. Madhavan S, Gauba R, Clarke R, Gusev Y. Integrative analysis workflow for untargeted metabolomics in translational research. *Metabolomics.* 2014; 4:130.
27. Wishart DS, et al. HMDB 3.0 — the human metabolome database in 2013. *Nucleic Acids Res.* 2013; 41:D801–D807. [PubMed: 23161693]
28. Kanehisa M, et al. From genomics to chemical genomics: new developments in KEGG. *Nucleic Acids Res.* 2006; 34:D354–D357. [PubMed: 16381885]
29. Fahy E, et al. Update of the LIPID MAPS comprehensive classification system for lipids. *J Lipid Res.* 2009; 50:S9–S14. [PubMed: 19098281]
30. Wheeler DL, et al. Database resources of the National Center for Biotechnology Information. *Nucleic Acids Res.* 2007; 35:D5–D12. [PubMed: 17170002]
31. Degtyarenko K, et al. ChEBI: a database and ontology for chemical entities of biological interest. *Nucleic Acids Res.* 2008; 36:D344–D350. [PubMed: 17932057]

32. Cui Q, et al. Metabolite identification via the Madison Metabolomics Consortium Database. *Nat Biotechnol.* 2008; 26:162–164. [PubMed: 18259166]
33. Smith CA, et al. METLIN: a metabolite mass spectral database. *Ther Drug Monit.* 2005; 27:747–751. [PubMed: 16404815]
34. Horai H, et al. MassBank: a public repository for sharing mass spectral data for life sciences. *J Mass Spectrom.* 2010; 45:703–714. [PubMed: 20623627]
35. Fiehn O, et al. The metabolomics standards initiative (MSI). *Metabolomics.* 2007; 3:175–178.
36. Oliver SG, Winson MK, Kell DB, Baganz F. Systematic functional analysis of the yeast genome. *Trends Biotechnol.* 1998; 16:373–378. [PubMed: 9744112]
37. Raamsdonk LM, et al. A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations. *Nat Biotechnol.* 2001; 19:45–50. [PubMed: 11135551]
38. Tweeddale H, Notley-McRobb L, Ferenci T. Effect of slow growth on metabolism of *Escherichia coli*, as revealed by global metabolite pool ('metabolome') analysis. *J Bacteriol.* 1998; 180:5109–5116. [PubMed: 9748443]
39. Kuehnbaum NL, Britz-McKibbin P. New advances in separation science for metabolomics: resolving chemical diversity in a post-genomic era. *Chem Rev.* 2013; 113:2437–2468. [PubMed: 23506082]
40. Goodacre R, Vaidyanathan S, Dunn WB, Harrigan GG, Kell DB. Metabolomics by numbers: acquiring and understanding global metabolite data. *Trends Biotechnol.* 2004; 22:245–252. [PubMed: 15109811]
41. Moco S, Bino RJ, De Vos RC, Vervoort J. Metabolomics technologies and metabolite identification. *Trends Anal Chem.* 2007; 26:855–866.
42. Dumas ME, et al. Assessment of analytical reproducibility of  $^1\text{H}$  NMR spectroscopy based metabolomics for large-scale epidemiological research: the INTERMAP Study. *Anal Chem.* 2006; 78:2199–2208. [PubMed: 16579598]
43. Viant MR, et al. International NMR-based environmental metabolomics intercomparison exercise. *Environ Sci Technol.* 2009; 43:219–225. [PubMed: 19209610]
44. Whitfield PD, German AJ, Noble PJ. Metabolomics: an emerging post-genomic tool for nutrition. *Br J Nutr.* 2004; 92:549–555. [PubMed: 15522124]
45. Wishart DS. Quantitative metabolomics using NMR. *Trends Anal Chem.* 2008; 27:228–237.
46. Zhang S, Nagana Gowda GA, Ye T, Raftery D. Advances in NMR-based biofluid analysis and metabolite profiling. *Analyst.* 2010; 135:1490–1498. [PubMed: 20379603]
47. Swanson MG, et al. Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues. *Magn Reson Med.* 2003; 50:944–954. [PubMed: 14587005]
48. Bhattacharya A. Chemistry: breaking the billion-hertz barrier. *Nature.* 2010; 463:605–606. [PubMed: 20130626]
49. Kovacs H, Moskau D, Spraul M. Cryogenically cooled probes — a leap in NMR technology. *Prog Nucl Magn Reson Spectrosc.* 2005; 46:131–155.
50. Molinski TF. NMR of natural products at the 'nanomole-scale'. *Nat Prod Rep.* 2010; 27:321–329. [PubMed: 20179874]
51. Styles P, et al. A high-resolution NMR probe in which the coil and preamplifier are cooled with liquid helium. *J Magn Reson.* 2011; 213:347–354. [PubMed: 22152353]
52. Tiziani S, Kang Y, Choi JS, Roberts W, Paternostro G. Metabolomic high-content nuclear magnetic resonance-based drug screening of a kinase inhibitor library. *Nat Commun.* 2011; 2:545. [PubMed: 22109519]
53. Birkemeyer C, Luedemann A, Wagner C, Erban A, Kopka J. Metabolome analysis: the potential of *in vivo* labeling with stable isotopes for metabolite profiling. *Trends Biotechnol.* 2005; 23:28–33. [PubMed: 15629855]
54. Guennec AL, Giraudeau P, Caldarelli S. Evaluation of fast 2D NMR for metabolomics. *Anal Chem.* 2014; 86:5946–5954. [PubMed: 24856256]



55. Hyberts SG, et al. Ultrahigh-resolution  $^1\text{H}$ - $^{13}\text{C}$  HSQC spectra of metabolite mixtures using nonlinear sampling and forward maximum entropy reconstruction. *J Am Chem Soc.* 2007; 129:5108–5116. [PubMed: 17388596]
56. Bouatra S, et al. The human urine metabolome. *PLoS ONE.* 2013; 8:e73076. [PubMed: 24023812]
57. Atherton HJ, et al. A combined  $^1\text{H}$ -NMR spectroscopy- and mass spectrometry-based metabolomic study of the PPAR- $\alpha$  null mutant mouse defines profound systemic changes in metabolism linked to the metabolic syndrome. *Physiol Genomics.* 2006; 27:178–186. [PubMed: 16868074]
58. Chan EC, et al. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). *J Proteome Res.* 2009; 8:352–361. [PubMed: 19063642]
59. Pan Z, Raftery D. Comparing and combining NMR spectroscopy and mass spectrometry in metabolomics. *Anal Bioanal Chem.* 2007; 387:525–527. [PubMed: 16955259]
60. Psychogios N, et al. The human serum metabolome. *PLoS ONE.* 2011; 6:e16957. [PubMed: 21359215]
61. Tiziani S, et al. Metabolomics of the tumor microenvironment in pediatric acute lymphoblastic leukemia. *PLoS ONE.* 2013; 8:e82859. [PubMed: 24349380]
62. Hol apek M, Jirásko R, Lísá M. Recent developments in liquid chromatography–mass spectrometry and related techniques. *J Chromatogr A.* 2012; 1259:3–15. [PubMed: 22959775]
63. Dettmer K, Aronov PA, Hammock BD. Mass spectrometry-based metabolomics. *Mass Spectrom Rev.* 2007; 26:51–78. [PubMed: 16921475]
64. Forcisi S, et al. Liquid chromatography–mass spectrometry in metabolomics research: mass analyzers in ultra high pressure liquid chromatography coupling. *J Chromatogr A.* 2013; 1292:51–65. [PubMed: 23631876]
65. Koulman A, et al. High-throughput direct-infusion ion trap mass spectrometry: a new method for metabolomics. *Rapid Commun Mass Spectrom.* 2007; 21:421–428. [PubMed: 17206744]
66. Han X, Gross RW. Shotgun lipidomics: electrospray ionization mass spectrometric analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples. *Mass Spectrom Rev.* 2005; 24:367–412. [PubMed: 15389848]
67. Han X, Yang K, Gross RW. Multi-dimensional mass spectrometry-based shotgun lipidomics and novel strategies for lipidomic analyses. *Mass Spectrom Rev.* 2012; 31:134–178. [PubMed: 21755525]
68. Kvitvang HF, Andreassen T, Adam T, Villas-Bôas SG, Bruheim P. Highly sensitive GC/MS/MS method for quantitation of amino and nonamino organic acids. *Anal Chem.* 2011; 83:2705–2711. [PubMed: 21388201]
69. Quehenberger O, Armando AM, Dennis EA. High sensitivity quantitative lipidomics analysis of fatty acids in biological samples by gas chromatography–mass spectrometry. *Biochim Biophys Acta.* 2011; 1811:648–656. [PubMed: 21787881]
70. Contrepolis K, Jiang L, Snyder M. Optimized analytical procedures for the untargeted metabolomic profiling of human urine and plasma by combining hydrophilic interaction (HILIC) and reverse-phase liquid chromatography (RPLC)-mass spectrometry. *Mol Cell Proteomics.* 2015; 14:1684–1695. [PubMed: 25787789]
71. Tautenhahn R, Böttcher C, Neumann S. Highly sensitive feature detection for high resolution LC/MS. *BMC Bioinformatics.* 2008; 9:504. [PubMed: 19040729]
72. Sturm S, Seger C. Liquid chromatography–nuclear magnetic resonance coupling as alternative to liquid chromatography–mass spectrometry hyphenations: curious option or powerful and complementary routine tool? *J Chromatogr A.* 2012; 1259:50–61. [PubMed: 22658656]
73. Rodrigues TB, et al. Magnetic resonance imaging of tumor glycolysis using hyperpolarized  $^{13}\text{C}$ -labeled glucose. *Nat Med.* 2014; 20:93–97. [PubMed: 24317119]
74. Fan TW, et al. Altered regulation of metabolic pathways in human lung cancer discerned by  $^{13}\text{C}$  stable isotope-resolved metabolomics (SIRM). *Mol Cancer.* 2009; 8:41. [PubMed: 19558692]
75. Günther, UL., et al. *Tumor Cell Metabolism.* Mazurek, S.; Shosha, M., editors. Springer; 2015. p. 315-348.

76. Priori R, et al. Metabolomics in rheumatic diseases: the potential of an emerging methodology for improved patient diagnosis, prognosis, and treatment efficacy. *Autoimmun Rev.* 2013; 12:1022–1030. [PubMed: 23688955]
77. Ouyang X, Dai Y, Wen JL, Wang L. X <sup>1</sup>H NMR-based metabolomic study of metabolic profiling for systemic lupus erythematosus. *Lupus.* 2011; 20:1411–1420. [PubMed: 21976403]
78. Wu T, et al. Metabolic disturbances associated with systemic lupus erythematosus. *PLoS ONE.* 2012; 7:e37210. [PubMed: 22723834]
79. Romick-Rosendale LE, et al. Identification of urinary metabolites that distinguish membranous lupus nephritis from proliferative lupus nephritis and focal segmental glomerulosclerosis. *Arthritis Res Ther.* 2011; 13:R199. [PubMed: 22152586]
80. Ding X, et al. Rapid resolution liquid chromatography coupled with quadrupole time-of-flight mass spectrometry-based metabolomics approach to study the effects of jieduquyuzyin prescription on systemic lupus erythematosus. *PLoS ONE.* 2014; 9:e88223. [PubMed: 24505438]
81. Kang SW, et al. 12-lipoxygenase is increased in glucose-stimulated mesangial cells and in experimental diabetic nephropathy. *Kidney Int.* 2001; 59:1354–1362. [PubMed: 11260396]
82. Adams SB Jr, et al. Global metabolic profiling of human osteoarthritic synovium. *Osteoarthritis Cartilage.* 2012; 20:64–67. [PubMed: 22063369]
83. Zhang W, et al. Classification of osteoarthritis phenotypes by metabolomics analysis. *BMJ Open.* 2014; 4:e006286.
84. Mickiewicz B, et al. Metabolic analysis of knee synovial fluid as a potential diagnostic approach for osteoarthritis. *J Orthop Res.* 2015; 33:1631–1638. [PubMed: 26010167]
85. Damyanovich AZ, Staples JR, Chan AD, Marshall KW. Comparative study of normal and osteoarthritic canine synovial fluid using 500 MHz <sup>1</sup>H magnetic resonance spectroscopy. *J Orthop Res.* 1999; 17:223–231. [PubMed: 10221839]
86. Damyanovich AZ, Staples JR, Marshall K. W <sup>1</sup>H NMR investigation of changes in the metabolic profile of synovial fluid in bilateral canine osteoarthritis with unilateral joint denervation. *Osteoarthritis Cartilage.* 1999; 7:165–172. [PubMed: 1022215]
87. Hügle T, et al. Synovial fluid metabolomics in different forms of arthritis assessed by nuclear magnetic resonance spectroscopy. *Clin Exp Rheumatol.* 2012; 30:240–245. [PubMed: 22410098]
88. Lacitignola L, Fanizzi FP, Francioso E, Crovace A. <sup>1</sup>H NMR investigation of normal and osteoarthritic synovial fluid in the horse. *Vet Comp Orthop Traumatol.* 2008; 21:85–88. [PubMed: 18288348]
89. Zhai G, et al. Serum branched-chain amino acid to histidine ratio: a novel metabolomic biomarker of knee osteoarthritis. *Ann Rheum Dis.* 2010; 69:1227–1231. [PubMed: 20388742]
90. Lamers RJ, et al. Identification of an urinary metabolite profile associated with osteoarthritis. *Osteoarthritis Cartilage.* 2005; 13:762–768. [PubMed: 15951202]
91. Zhang W, et al. Relationship between blood plasma and synovial fluid metabolite concentrations in patients with osteoarthritis. *J Rheumatol.* 2015; 42:859–865. [PubMed: 25729031]
92. Kim S, et al. Global metabolite profiling of synovial fluid for the specific diagnosis of rheumatoid arthritis from other inflammatory arthritis. *PLoS ONE.* 2014; 9:e97501. [PubMed: 24887281]
93. Giera M, et al. Lipid and lipid mediator profiling of human synovial fluid in rheumatoid arthritis patients by means of LC-MS/MS. *Biochim Biophys Acta.* 2012; 1821:1415–1424. [PubMed: 22841830]
94. Kosinska MK, et al. A lipidomic study of phospholipid classes and species in human synovial fluid. *Arthritis Rheum.* 2013; 65:2323–2333. [PubMed: 23784884]
95. Jiang M, et al. Serum metabolic signatures of four types of human arthritis. *J Proteome Res.* 2013; 12:3769–3779. [PubMed: 23819623]
96. Young SP, et al. The impact of inflammation on metabolomic profiles in patients with arthritis. *Arthritis Rheum.* 2013; 65:2015–2023. [PubMed: 23740368]
97. Madsen RK, et al. Diagnostic properties of metabolic perturbations in rheumatoid arthritis. *Arthritis Res Ther.* 2011; 13:R19. [PubMed: 21303541]

98. van Wietmarschen HA, et al. Characterization of rheumatoid arthritis subtypes using symptom profiles, clinical chemistry and metabolomics measurements. *PLoS ONE*. 2012; 7:e44331. [PubMed: 22984493]
99. Armstrong AW, et al. Metabolomics in psoriatic disease: pilot study reveals metabolite differences in psoriasis and psoriatic arthritis. *PLoS Res*. 2014; 3:248. [PubMed: 25580230]
100. Fischer R, et al. Discovery of candidate serum proteomic and metabolomic biomarkers in ankylosing spondylitis. *Mol Cell Proteomics*. 2012; 11013904:M111. [PubMed: 21997733]
101. Gao P, et al. Integrated GC-MS and LC-MS plasma metabolomics analysis of ankylosing spondylitis. *Analyst*. 2008; 133:1214–1220. [PubMed: 18709197]
102. Ding X, et al. Metabolomics analysis of collagen-induced arthritis in rats and interventional effects of oral tolerance. *Anal Biochem*. 2014; 458:49–57. [PubMed: 24814225]
103. Wang Z, et al. <sup>1</sup>H NMR-based metabolomic analysis for identifying serum biomarkers to evaluate methotrexate treatment in patients with early rheumatoid arthritis. *Exp Ther Med*. 2012; 4:165–171. [PubMed: 23060942]
104. Kapoor SR, et al. Metabolic profiling predicts response to anti-tumor necrosis factor  $\alpha$  therapy in patients with rheumatoid arthritis. *Arthritis Rheum*. 2013; 65:1448–1456. [PubMed: 23460124]
105. Ghesquière B, Wong BW, Kuchnio A, Carmeliet P. Metabolism of stromal and immune cells in health and disease. *Nature*. 2014; 511:167–176. [PubMed: 25008522]
106. Maciolek JA, Pasternak JA, Wilson HL. Metabolism of activated T lymphocytes. *Curr Opin Immunol*. 2014; 27:60–74. [PubMed: 24556090]
107. MacIver NJ, Michalek RD, Rathmell JC. Metabolic regulation of T lymphocytes. *Annu Rev Immunol*. 2013; 31:259–283. [PubMed: 23298210]
108. Palmer CS, Ostrowski M, Balderson B, Christian N, Crowe SM. Glucose metabolism regulates T cell activation, differentiation, and functions. *Front Immunol*. 2015; 6:1. [PubMed: 25657648]
109. Pearce EL, Poffenberger MC, Chang CH, Jones RG. Fueling immunity: insights into metabolism and lymphocyte function. *Science*. 2013; 342:1242454. [PubMed: 24115444]
110. Wang R, Green DR. Metabolic reprogramming and metabolic dependency in T cells. *Immunol Rev*. 2012; 249:14–26. [PubMed: 22889212]
111. Galván-Peña S, O'Neill LA. Metabolic reprogramming in macrophage polarization. *Front Immunol*. 2014; 5:420. [PubMed: 25228902]
112. Everts B, Pearce EJ. Metabolic control of dendritic cell activation and function: recent advances and clinical implications. *Front Immunol*. 2014; 5:203. [PubMed: 24847328]
113. Pearce EJ, Everts B. Dendritic cell metabolism. *Nat Rev Immunol*. 2015; 15:18–29. [PubMed: 25534620]
114. Yin Y, et al. Normalization of CD4+ T cell metabolism reverses lupus. *Sci Transl Med*. 2015; 7:274ra218.
115. McDonald G, et al. Normalizing glycosphingolipids restores function in CD4+ T cells from lupus patients. *J Clin Invest*. 2014; 124:712–724. [PubMed: 24463447]
116. Yang Z, Fujii H, Mohan SV, Goronzy JJ, Weyand CM. Phosphofructokinase deficiency impairs ATP generation, autophagy, and redox balance in rheumatoid arthritis T cells. *J Exp Med*. 2013; 210:2119–2134. [PubMed: 24043759]
117. Bottini N, Firestein GS. Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors. *Nat Rev Rheumatol*. 2013; 9:24–33. [PubMed: 23147896]
118. Garcia-Carbonell, R., et al. Critical role of fibroblast-like synoviocytes glycolytic metabolism in rheumatoid arthritis. *Arthritis Rheumatol*. 2016. <http://dx.doi.org/10.1002/art.39608>
119. Guma M, et al. Choline kinase inhibition in rheumatoid arthritis. *Ann Rheum Dis*. 2014; 74:1399–1407. [PubMed: 25274633]
120. Glunde K, Bhujwala ZM, Ronen SM. Choline metabolism in malignant transformation. *Nat Rev Cancer*. 2011; 11:835–848. [PubMed: 22089420]
121. Jiménez B, del Peso L, Montaner S, Esteve P, Lacal JC. Generation of phosphorylcholine as an essential event in the activation of Raf-1 and MAP-kinases in growth factors-induced mitogenic stimulation. *J Cell Biochem*. 1995; 57:141–149. [PubMed: 7721953]

122. Ramírez de Molina A, et al. Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression. *Cancer Res.* 2004; 64:6732–6739. [PubMed: 15374991]
123. Ramírez de Molina A, et al. Choline kinase as a link connecting phospholipid metabolism and cell cycle regulation: implications in cancer therapy. *Int J Biochem Cell Biol.* 2008; 40:1753–1763. [PubMed: 18296102]
124. Ramírez de Molina A, et al. Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. *Lancet Oncol.* 2007; 8:889–897. [PubMed: 17851129]
125. Baker DA, Eudaly J, Smith CD, Obeid LM, Gilkeson GS. Impact of sphingosine kinase 2 deficiency on the development of TNF-alpha-induced inflammatory arthritis. *Rheumatol Int.* 2013; 33:2677–2681. [PubMed: 23011090]
126. Hu PF, Chen Y, Cai PF, Jiang LF, Wu LD. Sphingosine-1-phosphate: a potential therapeutic target for rheumatoid arthritis. *Mol Biol Rep.* 2011; 38:4225–4230. [PubMed: 21116853]
127. Zhao C, et al. Specific and overlapping sphingosine-1-phosphate receptor functions in human synoviocytes: impact of TNF- $\alpha$ . *J Lipid Res.* 2008; 49:2323–2337. [PubMed: 18658144]
128. Bourgoin SG, Zhao C. Autotaxin and lysophospholipids in rheumatoid arthritis. *Curr Opin Investig Drugs.* 2010; 11:515–526.
129. Leah E. Experimental arthritis: pathogenic role of autotaxin and LPA. *Nat Rev Rheumatol.* 2012; 8:307. [PubMed: 22647775]
130. Nikitopoulou I, et al. Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled arthritis. *J Exp Med.* 2012; 209:925–933. [PubMed: 22493518]
131. Fuchs B, Schiller J, Wagner U, Häntzschel H, Arnold K. The phosphatidylcholine/lysophosphatidylcholine ratio in human plasma is an indicator of the severity of rheumatoid arthritis: investigations by  $^{31}\text{P}$  NMR and MALDI-TOF MS. *Clin Biochem.* 2005; 38:925–933. [PubMed: 16043165]
132. Dang CV, Hamaker M, Sun P, Le A, Gao P. Therapeutic targeting of cancer cell metabolism. *J Mol Med (Berl).* 2011; 89:205–212. [PubMed: 21301795]
133. Ramsay EE, Hogg PJ, Dilda PJ. Mitochondrial metabolism inhibitors for cancer therapy. *Pharm Res.* 2011; 28:2731–2744. [PubMed: 21918915]
134. Vander Heiden MG. Targeting cancer metabolism: a therapeutic window opens. *Nat Rev Drug Discov.* 2011; 10:671–684. [PubMed: 21878982]
135. Wenger JB, Chun SY, Dang DT, Luesch H, Dang LH. Combination therapy targeting cancer metabolism. *Med Hypotheses.* 2011; 76:169–172. [PubMed: 20947261]
136. Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. *Cell Death Dis.* 2013; 4:e532. [PubMed: 23470539]
137. Galluzzi L, Kepp O, Vander Heiden MG, Kroemer G. Metabolic targets for cancer therapy. *Nat Rev Drug Discov.* 2013; 12:829–846. [PubMed: 24113830]
138. Schulze A, Harris AL. How cancer metabolism is tuned for proliferation and vulnerable to disruption. *Nature.* 2012; 491:364–373. [PubMed: 23151579]
139. Meier FM, Frerix M, Hermann W, Müller-Ladner U. Current immunotherapy in rheumatoid arthritis. *Immunotherapy.* 2013; 5:955–974. [PubMed: 23998731]
140. Cardaci S, Desideri E, Ciriolo MR. Targeting aerobic glycolysis: 3-bromopyruvate as a promising anticancer drug. *J Bioenerg Biomembr.* 2012; 44:17–29. [PubMed: 22328057]
141. Pedersen PL. 3-bromopyruvate (3BP) a fast acting, promising, powerful, specific, and effective ‘small molecule’ anti-cancer agent taken from labside to bedside: introduction to a special issue. *J Bioenerg Biomembr.* 2012; 44:1–6. [PubMed: 22382780]
142. Le A, et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. *Proc Natl Acad Sci USA.* 2010; 107:2037–2042. [PubMed: 20133848]
143. Liu Y, et al. A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth *in vitro* and *in vivo*. *Mol Cancer Ther.* 2012; 11:1672–1682. [PubMed: 22689530]

144. Schneiderhan W, et al. CD147 silencing inhibits lactate transport and reduces malignant potential of pancreatic cancer cells in *in vivo* and *in vitro* models. *Gut*. 2009; 58:1391–1398. [PubMed: 19505879]
145. Patra KC, et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. *Cancer Cell*. 2013; 24:213–228. [PubMed: 23911236]
146. Robey RB, Hay N. Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. *Oncogene*. 2006; 25:4683–4696. [PubMed: 16892082]
147. Wilson JE. Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. *J Exp Biol*. 2003; 206:2049–2057. [PubMed: 12756287]
148. Stark AK, Sriskantharajah S, Hessel EM, Okkenhaug K. PI3K inhibitors in inflammation, autoimmunity and cancer. *Curr Opin Pharmacol*. 2015; 23:82–91. [PubMed: 26093105]
149. Banham-Hall E, Clatworthy MR, Okkenhaug K. The therapeutic potential for PI3K inhibitors in autoimmune rheumatic diseases. *Open Rheumatol J*. 2012; 6:245–258. [PubMed: 23028409]
150. Roberts E, Guerrero M, Urbano M, Rosen H. Sphingosine 1-phosphate receptor agonists: a patent review. *Expert Opin Ther Pat*. 2013; 23:817–841. [PubMed: 23541049]
151. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. *Nat Rev Cancer*. 2007; 7:763–777. [PubMed: 17882277]
152. Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. *Trends Biochem Sci*. 2010; 35:427–433. [PubMed: 20570523]
153. Seguin F, et al. The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas. *Br J Cancer*. 2012; 107:977–987. [PubMed: 22892389]
154. Hatzivassiliou G, et al. ATP citrate lyase inhibition can suppress tumor cell growth. *Cancer Cell*. 2005; 8:311–321. [PubMed: 16226706]
155. Beckers A, et al. Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. *Cancer Res*. 2007; 67:8180–8187. [PubMed: 17804731]
156. Hernández-Alcoceba R, Fernández F, Lacal JC. *In vivo* antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery. *Cancer Res*. 1999; 59:3112–3118. [PubMed: 10397253]
157. Lacal JC. Choline kinase: a novel target for antitumor drugs. *IDrugs*. 2001; 4:419–426. [PubMed: 16015482]
158. Nomura DK, et al. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. *Cell*. 2010; 140:49–61. [PubMed: 20079333]
159. Ghosh-Choudhury N, Mandal CC, Ghosh-Choudhury N, Ghosh-Choudhury G. Simvastatin induces derepression of PTEN expression via NF $\kappa$ B to inhibit breast cancer cell growth. *Cell Signal*. 2010; 22:749–758. [PubMed: 20060890]
160. Kaddurah-Daouk R, Weinshilboum RM, Pharmacometabolomics Research Network. Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology. *Clin Pharmacol Ther*. 2014; 95:154–167. [PubMed: 24193171]
161. Bordbar A, Monk JM, King ZA, Palsson BO. Constraint-based models predict metabolic and associated cellular functions. *Nat Rev Genet*. 2014; 15:107–120. [PubMed: 24430943]
162. Saha R, Chowdhury A, Maranas CD. Recent advances in the reconstruction of metabolic models and integration of omics data. *Curr Opin Biotechnol*. 2014; 29:39–45. [PubMed: 24632194]
163. Adamski J, Suhre K. Metabolomics platforms for genome wide association studies — linking the genome to the metabolome. *Curr Opin Biotechnol*. 2013; 24:39–47. [PubMed: 23102864]
164. Adamski J. Genome-wide association studies with metabolomics. *Genome Med*. 2012; 4:34. [PubMed: 22546499]
165. Holmes E, Li JV, Marchesi JR, Nicholson JK. Gut microbiota composition and activity in relation to host metabolic phenotype and disease risk. *Cell Metab*. 2012; 16:559–564. [PubMed: 23140640]
166. El Aidy S, et al. The gut microbiota elicits a profound metabolic reorientation in the mouse jejunal mucosa during conventionalisation. *Gut*. 2013; 62:1306–1314. [PubMed: 22722618]

167. Nicholson JK, et al. Host-gut microbiota metabolic interactions. *Science*. 2012; 336:1262–1267. [PubMed: 22674330]
168. Arpaia N, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. *Nature*. 2013; 504:451–455. [PubMed: 24226773]
169. Griffiths WJ, et al. Targeted metabolomics for biomarker discovery. *Angew Chem Int Ed Engl*. 2010; 49:5426–5445. [PubMed: 20629054]
170. Lagarde M, G elo en A, Record M, Vance D, Spener F. Lipidomics is emerging. *Biochim Biophys Acta*. 2003; 1634:61. [PubMed: 14643793]
171. Seeger K. Metabolic changes in autoimmune diseases. *Curr Drug Discov Technol*. 2009; 6:256–261. [PubMed: 20025593]
172. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. *Nat Rev Cancer*. 2011; 11:85–95. [PubMed: 21258394]
173. Courtney R, et al. Cancer metabolism and the Warburg effect: the role of HIF-1 and PI3K. *Mol Biol Rep*. 2015; 42:841–851. [PubMed: 25689954]
174. Elstrom RL, et al. Akt stimulates aerobic glycolysis in cancer cells. *Cancer Res*. 2004; 64:3892–3899. [PubMed: 15172999]
175. Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. *Cell*. 2008; 134:703–707. [PubMed: 18775299]
176. Chang CH, et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. *Cell*. 2013; 153:1239–1251. [PubMed: 23746840]
177. Patra KC, Hay N. The pentose phosphate pathway and cancer. *Trends Biochem Sci*. 2014; 39:347–354. [PubMed: 25037503]
178. Nagy C, Haschemi A. Time and demand are two critical dimensions of immunometabolism: the process of macrophage activation and the pentose phosphate pathway. *Front Immunol*. 2015; 6:164. [PubMed: 25904920]
179. Lochner M, Berod L, Sparwasser T. Fatty acid metabolism in the regulation of T cell function. *Trends Immunol*. 2015; 36:81–91. [PubMed: 25592731]
180. Schriever SC, Deutsch MJ, Adamski J, Roscher AA, Ensenaer R. Cellular signaling of amino acids towards mTORC1 activation in impaired human leucine catabolism. *J Nutr Biochem*. 2013; 24:824–831. [PubMed: 22898570]
181. DeBerardinis RJ, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. *Proc Natl Acad Sci USA*. 2007; 104:19345–19350. [PubMed: 18032601]
182. Pollizzi KN, Powell JD. Integrating canonical and metabolic signalling programmes in the regulation of T cell responses. *Nat Rev Immunol*. 2014; 14:435–446. [PubMed: 24962260]
183. Agathocleous M, Harris WA. Metabolism in physiological cell proliferation and differentiation. *Trends Cell Biol*. 2013; 23:484–492. [PubMed: 23756093]

**Key points**

- Along with other ‘omics’ approaches, metabolomics — the comprehensive analysis of all metabolites in a system — represents a change from the traditional analysis of single genes, transcripts, proteins or metabolites
- Improvements in analytical techniques and pattern-recognition methods have led to a rise in the numbers of untargeted and targeted metabolic studies that are being performed
- Understanding metabolic changes that are specifically associated with the pathogenesis of autoimmune diseases should lead to novel insights into disease mechanisms and to new strategies for treatment of rheumatic diseases
- The feasibility of metabolomics for biomarker discovery in rheumatology is supported by the assumption that metabolites are important players in biological systems and that diseases cause disruption of metabolic pathways

**Box 1****Definitions in metabolomics****Metabolism**

The sum total of all chemical reactions that occur in the cell. Metabolic processes are usually classified as catabolic, which usually release energy, and anabolic, which build new molecules and usually require energy.

**Metabolites**

Small biological compounds produced during metabolic activity, usually with a molecular mass below 1,500 Da. Typical metabolites include amino acids, carbohydrates, organic acids, lipids and nucleotides.

**Metabolome**

The entire set of metabolites present in a given compartment — such as a cell, tissue or body fluid — under a particular set of physiological conditions. The metabolome can include many heterogeneous molecules at a range of concentrations, including endogenous and exogenous metabolites. The cell metabolome can be divided into intracellular and extracellular metabolites, which constitute the endometabolome and exometabolome, respectively.

**Metabolomics**

A “comprehensive analysis in which all the metabolites of a biological system are identified and quantified” (REF. 4). As with other ‘omics’ techniques, metabolomics is an untargeted and comprehensive analysis.

**Metabolic profiling (metabolite target analysis)**

The identification and quantification of a predefined subset of metabolites associated with a specific metabolic pathway. Sometimes called targeted metabolomics<sup>169</sup>, a misnomer as metabolomics implies an untargeted approach.

**Metabolic fingerprinting**

A rapid, high-throughput metabolite analysis of biological samples (cells, tissue, blood or urine) to determine the health status of an organism.

**Metabolic footprinting**

The analysis of metabolites excreted and secreted by prokaryotic and eukaryotic cells (the exometabolome).

**Lipidomics**

A subdivision of metabolomics, defined as “the full characterization of lipid molecular species and of their biological roles with respect to expression of proteins involved in lipid metabolism and function, including gene regulation” (REF. 170).

**Stable-isotope-assisted metabolomics**



Metabolomic analysis following stable isotope incorporation, as in metabolic-flux-balance analysis using  $^{13}\text{C}$  tracer.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

**Box 2****Pros and cons of current metabolomics technologies****Pros of gas-chromatography mass spectrometry (GC–MS)**

- Detection of subpicomolar concentrations possible; can detect 200 metabolites per sample
- Good relative quantification
- Moderate mass accuracy (<50 ppm), improved by GC coupled to Orbitrap MS
- Minimal sample requirement
- Analysis of volatile compounds does not require derivatization
- Benchtop instrumentation
- Relatively inexpensive instrumentation (<USD\$100,000)
- Moderate instrumentation warranty cost

**Cons of GC–MS**

- Injected sample cannot be recovered
- Derivatization or extensive sample preparation required for nonvolatile metabolites
- Derivatization procedures vary and can lead to formation of several products from a single metabolite
- Stereoisomers not identified

**Pros of liquid-chromatography mass spectrometry (LC–MS)**

- Detection of subfemtomolar concentrations possible; can detect 1,000 metabolites per sample
- Outstanding mass accuracy (<1–3 ppm)
- Detects wide size range of metabolites (> 50 Da)
- Minimal sample requirement
- Good relative quantification
- Increasing number of benchtop instruments becoming available
- Metabolite imaging possible with matrix-assisted laser desorption ionization (MALDI)

**Cons of LC–MS**

- Sample unrecoverable
- Molecular ionization susceptible to sample–matrix effects

- Requires isotopically enriched internal standards for absolute quantification
- Stereoisomers not identified
- Moderately expensive instrumentation (>\$300,000–\$1,000,000)

**Pros of NMR**

- Unbiased
- Nondestructive
- Definitive chemical structural identification
- Provides relative and absolute quantification
- Rapid acquisition of 1D<sup>1</sup>H spectra (1–5 min)
- Minimal sample preparation
- No chromatographic separation required
- Outstanding reproducibility (>98%)
- Metabolites detected in solution, semi-solid and solid samples
- Stereoisomers can be identified
- Can be applied *in vivo*

**Disadvantages of NMR**

- Nanomolar detection range of ~50–200 metabolites per sample
- Slow acquisition for 2D spectra ( 4 h)
- Majority of NMR probes require large sample volume (160–600 µl)
- High magnetic-field precludes benchtop instrumentation
- Expensive instrumentation (>\$500,000–\$2,000,000)


**Box 3****Metabolic changes in activated cells**

Activated<sup>13,105,106,171</sup> or malignant<sup>172–175</sup> cells shift from oxidative phosphorylation to glycolysis for ATP generation (FIG. 2). Although the glycolytic pathway is an inefficient way to produce ATP from glucose, the glycolytic intermediates can be used as precursors for nucleotide, amino acid, phospholipid and triglyceride biosynthesis. Nonmetabolic functions of glycolytic enzymes have been described<sup>176</sup>. Glycolytic products such as lactic acid<sup>14</sup> and succinate<sup>17</sup> can function as signalling molecules to control transcriptional responses.

The PPP is required for the synthesis of ribonucleotides and is a major source of NADPH<sup>177</sup>, which is required for and consumed during fatty acid synthesis and the scavenging reactive oxygen species. The PPP enables glycolytic cells to meet their anabolic demands and combat oxidative stress. A glycolysis–PPP axis is also involved in M1 macrophage polarization<sup>178</sup>.


Fatty acid metabolism is increased in tumour cells, generating novel phospholipid bilayers<sup>151</sup>. Enzymes that catalyse the generation of fatty acids, such as fatty acid synthase, or phospholipids, such as choline kinase, have important roles in lipid biosynthesis and can alter lipid compositions in cellular membranes in tumours as well as regulate cellular functions<sup>23</sup>. The development and function of different T cell subsets are closely linked to the predominant usage of fatty acid synthesis rather than fatty acid oxidation<sup>179</sup>. Short-chain fatty acids, such as butyrate and propionate, which are recognized mainly by G protein-coupled receptors such as GPR43 regulate the induction and homeostasis of T regulatory (T<sub>REG</sub>) cells<sup>168</sup>.

Cell activation increases rates of amino acid uptake by increasing expression of key amino acid transporters<sup>180</sup>. Branched-chain and aromatic amino acids, such as leucine, isoleucine, tryptophan and phenylalanine are used for *de novo* protein synthesis. Glutamine can be metabolized to lactate via glutaminolysis to support fatty acid synthesis<sup>181</sup>.



**Figure 1. Overview of major metabolic pathways**

Cellular metabolic pathways include synthesis of lipids, glycogen and nucleotides, glycolysis (the breakdown of carbohydrates and sugars to produce ATP and pyruvic acid) and the hexokinase pathway, which gives rise to substrates for the synthesis of glycoproteins and glycolipids. Mitochondrial oxidative phosphorylation (the Krebs cycle) is the sequence of reactions by which most living cells generate energy during the process of aerobic respiration. Glutaminolysis occurs partly in the mitochondrion and partly in the cytosol, and is an important energy source in tumour cells. CoA, coenzyme A; CTP, citrate transport protein; MPC, mitochondrial pyruvate carrier; PRPP, phosphoribosyl pyrophosphate; UDP, uridine diphosphate.



**Figure 2. Metabolic alterations and signalling pathways involved in activated cells**

Activated cells take up large amounts of glucose and glutamine and divert them to the pentose-phosphate pathway (PPP) and lipid biosynthesis, respectively. Coupled to an increased uptake of glycine, serine and branched chain amino acids (leucine, isoleucine and valine), which are required for protein synthesis, this diversion generates sufficient building blocks (nucleic acids, proteins and membranes) for proliferation. The increased generation of reactive oxygen species requires appropriate levels of antioxidants, most of which originate from the PPP. These metabolic changes generate bioactive metabolites that are secreted, and that also contribute to cell activation. Numerous signalling pathways are involved in metabolic changes in activated cells<sup>182,183</sup>. 3-PG, 3-phosphoglycerate; A-KG,  $\alpha$ -ketoglutarate; AKT, protein kinase B; AMPK, AMP-activated protein kinase; CoA, coenzyme A; G6P, glucose-6-phosphate; HIF-1, hypoxia-inducible factor 1; L-AA, L-amino acid; LPA, lysophosphatidic acid; Myc, Myc proto-oncogene protein; p53, cellular tumour antigen p53; PI3K, phosphatidylinositol 4,5-bisphosphate 3-kinase; R5P, ribose-5-phosphate; S1P, sphingosine-1-phosphate; SREBP, sterol regulatory element-binding protein.

**Table 1**

## Biological effects of key metabolites

Metabolite	Molecular effect	Examples of responsive cells	Cell response
<i>Organic compounds</i>			
Lactate	HIF-1 $\alpha$ stabilization	• Tumour cells • DCs	• Angiogenic signalling • Differentiation to IL-10-producing DCs
Kynurenine	ND	T cells	T <sub>H</sub> 2 cell polarization
Succinate	HIF-1 $\alpha$ stabilization	Macrophages	IL-1 $\beta$ expression
Acetyl coenzyme A	Histone-acetyltransferase activity	Tumour cells	Changes in energy homeostasis
<i>Amino acids or peptides</i>			
Branched amino acids	mTOR signalling	Macrophages	IL-1 $\beta$ expression
Glutathione	Antioxidant activity	T cells	T-cell proliferation
<i>Lipids</i>			
PIP3	Protein kinase B (AKT) signalling	Fibroblasts	Cell growth, proliferation and migration
Ceramides	ND	Tumour cells	Apoptosis
Sphingosine-1-phosphate	MAPK/PLC/PI3K signalling	T cells	Migration
LPA	G-protein-coupled receptor signalling	Fibroblasts, T cells	Proliferation, migration
Butyrate	Deacetylase inhibition	DCs and T cells	Induction of tolerogenic DCs, T-cell apoptosis
Oxysterols	Pro-inflammatory gene regulation	DCs	Enhanced DC immunogenicity
<i>Nucleotides</i>			
ATP	ND	DCs	Induction of tolerogenic DCs

DCs, dendritic cells; HIF-1 $\alpha$ , hypoxia-inducible factor 1 $\alpha$ ; LPA, lysophosphatidic acid; MAPK, mitogen-activated protein kinase; mTOR, mammalian target of rapamycin; ND, not determined; PI3K, phosphatidylinositol 4,5-bisphosphate 3-kinase; PIP3, phosphatidylinositol (3,4,5)-trisphosphate; PLC, phospholipase C; T<sub>H</sub>2, type 2 T helper.